

Review Article

A novel experimental and clinical research on pathogenic and cellular mechanisms, transmission, diagnostic and clinical treatment of COVID-19 infection

Alireza Heidari^{1,2,3,4,5 *}

¹Department of Biology, Spelman College, 350 Spelman Lane Southwest, Atlanta, GA, USA.

²Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA, USA.

³BioSpectroscopy Core Research Laboratory (BCRL), California South University, CA, USA.

⁴Cancer Research Institute (CRI), California South University, CA, USA.

⁵American International Standards Institute (AISI), Irvine, CA, USA.

Abstract. Coronaviruses are a large family of viruses that cause a variety of illnesses, from the common cold to severe acute respiratory syndrome. The SARS-COV-2 outbreak was first reported by the World Health Organization in China and has now become an epidemic, reflecting the extremely high transmissibility of the virus, which has caused great concern and stress among people around the world. Research suggests that prevention, risk education, and promotion of self-care behaviors can slow the spread of the disease in communities, and identifying sources of transmission can be effective in controlling it. The mortality rate of this virus is significantly higher in the elderly and people with underlying diseases compared to healthy people. Coronavirus is a challenging disease and can be easily transmitted in public places, and the number of people infected with this virus is increasing exponentially across all ages and groups. Therefore, increasing public awareness of this disease and providing positive psychological programs and teaching prevention methods in the media can reduce mental problems in society, in addition to reducing mortality and the number of patients.

Keywords: COVID-19, outbreak, prevention, treatment.


Introduction

Coronaviruses are a group of viruses that were first identified in 1960. These viruses infect humans and other vertebrates. In recent decades, infections of the coronavirus family have affected the respiratory system, digestive system, liver, and central nervous system of humans, livestock, birds, bats, mice, and many other wild animals, and have manifested themselves with mild to moderate symptoms, often in the form of common colds. Its new mutant type, called COVID-19, emerged and spread in China at the end of 2019 (beginning of December 2019), and the pandemic of this virus caused about 140 countries around the world to be infected with this disease in the last week of 2019. Our country is no exception to this rule. The first cases of the disease were found and announced in Qom on Wednesday, February 19, and by the time this article was submitted, cases of the disease had been

reported in all provinces of the country [1]. Studies suggest that SARS and MERS originated in bats, infected an intermediate host, and then jumped to humans. It is possible that COVID-19 also originated in bats, which varies depending on the region and species of bat [2].

In general, coronaviruses cause mild respiratory illness in humans with symptoms similar to the common cold. Of the seven coronaviruses that can infect people, four cause the common cold, alpha coronaviruses NL63 and 229E, and beta coronaviruses HKU1 and OC43, and three cause more severe disease, including severe acute respiratory syndrome coronavirus (SARS), Middle East respiratory syndrome coronavirus (MERS), and a novel coronavirus identified in 2019 [4, 3]. These have also been shown to cause severe and even fatal respiratory illness. For example, the outbreak of the severe acute respiratory syndrome (SARS-CoV-1) in 2002 or the Middle East respiratory

* Corresponding author: Prof. Alireza Heidari
(Alireza.Heidari@calsu.us).



Schematics of epidemiological features, transmission routes, mechanism of pathogenesis and receptor utilization, clinical symptoms and pathogenesis, diagnosis, prevention, control and treatment of COVID-19 infection.

syndrome (MERS) in 2012, both caused by coronaviruses. Coronaviruses are members of the Coronaviridae family. They also have a common RNA genome.

Both viruses are transmitted from animals to humans [6, 5] and cause inflammation of the upper respiratory tract and then affect the lower respiratory tract, often resulting in fatal lung damage and death. The average incubation period, the time between infection with the infectious virus and the onset of symptoms and disease, is about 5–7 days (range 2–14 days) [7]. Coronaviruses have typically caused severe disease that is limited to a specific country or region in recent years [8]. The main and initial symptom of COVID-19 is fever, and acute respiratory symptoms appear about 5 days later. People with chronic underlying diseases and healthcare workers are at high risk of infection [9].

In order to help healthcare workers in the country better cope with the novel coronavirus-2019, we review the available studies and evidence related to it and present scientific and practical information in the present study.

Structure of the novel coronavirus

Coronavirus belongs to the family Coronaviridae and is a member of the order Nidovirales. Viruses in this family are enveloped viruses with a helical capsid and have a diameter of about 80 to 220 nm. On the surface of the lipid envelope of these viruses, there are glycoprotein appendages that give the virus a petal-shaped or crown-shaped appearance (Figure 1). The genome of these viruses consists of single-stranded RNA with positive polarity. Among viruses with RNA genomes, coronaviruses have the longest genome with a length of about 29 to 22 thousand base pairs [10].

So far, four genera of coronaviruses have been identified, namely alpha, beta, gamma and delta, and COVID-19 is placed in the genus beta coronavirus of the subfamily Coronavirinae [11–13]. Beta and alpha viruses infect only mammals and typically cause respiratory disease in humans and the stomachs of animals. Gamma and delta viruses infect birds, but some can also infect

mammals [14]. The coronavirus family has two different types of surface proteins and is named for this characteristic appearance.

COVID-19 is the third known animal coronavirus disease agent after SARS and MERS, which also belong to the beta coronavirus family [7]. Two highly pathogenic viruses, SARS and MERS, cause severe acute respiratory syndrome in humans, and the other four human agents (HCoV-NL63, HCoV-229E, HCoV-OC43, and HKU1) induce only mild upper respiratory disease. However, some can cause severe infection in immunocompromised individuals, infants, young children, and the elderly [15–17].

Origin of the novel coronavirus

The source of pneumonia was first discovered in December 2019 by doctors in Wuhan, China, and a novel coronavirus was isolated from the respiratory epithelium of patients, which belongs to the coronavirus family. On February 11, 2020, the new coronavirus was officially renamed from “SARS-CoV-2” to “COVID-2019” [18]. According to data released by the National Health Commission of the Republic of China, COVID-19 is most likely to have originated from wild cats [21–19] and from seafood, poultry, and live animal markets located in Wuhan, Hubei Province, central China [22, 23], and all three coronaviruses can be transmitted from person to person [21–19].

On January 1, 2020, the market was closed and decontaminated [22, 23]. On the same day, Wuhan authorities released information about the outbreak to the public [24]. Today, the number of COVID-19 cases worldwide is increasing exponentially.

The first genome sequence of COVID-19 was published online one day after it was confirmed by Zhang and other scientists at Fudan University in Shanghai [25]. Following this, on January 11, five additional genome sequences of the virus were uploaded to the GSAID database by various initiatives across China, allowing researchers around the world to begin research on this




Figure (1): Coronavirus body (enveloped with a helical capsid, approximately 80 to 220 nm in diameter and with glycoprotein appendages on the surface of the lipid envelope) [10].

novel coronavirus [26]. By January 17, 62 cases of this coronavirus had been confirmed in China and three outside China (two in Thailand and one in Japan) [27]. Subsequently, the genome sequences of all coronaviruses isolated in China and abroad were determined and uploaded to the database. Following the development of appropriate diagnostic kits, other suspected cases of the disease were identified in other parts of the world, including Vietnam, Singapore, and Hong Kong [28]. The successful isolation and sequencing of the 2010-nCoV genome has greatly contributed to understanding the origin of the virus and its infectious properties. However, many uncertainties remain, and scientists are currently conducting extensive research on this new virus.

Following the increase in cases and the global spread of this virus, the World Health Organization (WHO) declared the outbreak of the new coronavirus the sixth global public health emergency of international concern on January 30, 2020, which was considered a threat not only to China but also to all countries [29]. As a populous country, China has previously fought viral epidemics, including SARS in 2003 [30].

The recent outbreak of COVID-19 has already caused great damage to the global economy, and the national growth of the world, and especially China, in 2019 decreased for the past 30 years [31]. Therefore, the

cooperation of health workers, governments and the public is needed to prevent the spread of the new coronavirus. On 11 February, the World Health Organization named the new coronavirus disease COVID-19 (29), and on the same day, the International Committee on Taxonomy of Viruses (ICTV) changed the name of the virus that causes the disease from 2010-nCoV to SARS-Cov-2 [32].

Epidemiological features of COVID-19

Coronaviruses have a broad host range and are responsible for 15–30% of all colds. Immunity to viral surface antigens is likely to play a major role in protecting individuals, but reinfection with similar strains is common [33]. Heidari et al. reported that from January 10 to 24, 2020, the number of COVID-19 cases in China increased 31.4-fold. On February 23, 2020, the number of COVID-19 cases in China was 1,879, compared to January 10, 2020. They estimated the mortality rate for COVID-19 based on their patient population to be 84.2%. The researchers also found that the male-to-female mortality ratio was 25.3:1, the median age at death was 75 years, the median time from onset of symptoms to death was 14 days, and the median time from onset of symptoms to death was 11.5 days in those aged 70 years and older and 20 days in those aged <70 years. These findings suggest that the disease may progress more rapidly in older adults than in younger individuals [34].

Heidari et al. reported a median age of 59 years among 425 patients infected with COVID-19, 56% of whom were male, a median incubation period of 2.5 days, and approximately half of the adult patients were 60 years or older. In the early stages, the number of infected patients doubled. The transmission rate from an infected person was 2.2. Although 55% of the first patients infected with the 2019 novel coronavirus were not from the Hana Seafood Market, the number of unrelated cases has been increasing exponentially since late December 2019 [35].

COVID-19 outbreak in the world

Epidemiological studies have shown that coastal cats in the wildlife market in China were the direct source of SARS-CoV [36]. From the beginning of the outbreak to April 26, 2020, the latest global statistics on the spread of the coronavirus show that all countries on all continents of the world (Figure 2) are affected by this virus and the disease COVID-19, which has an overall mortality rate (2.98%) and a recovery rate (74.29%) [37] (Figure 2).

Transmission routes of COVID-19

The 2019 novel coronavirus is thought to be transmitted by droplets, close contact, aerosols, and perhaps fecal-oral transmission, and patients during the incubation period can transmit the virus to others [9, 11]. The distribution of the viral receptor may explain the pathogenic mechanisms, clinical manifestations, and




Figure 2: Global spread of COVID-19 (dark areas indicate affected countries) [37].

transmission routes of the 2019 novel coronavirus. Angiotensin-converting enzyme 2 (ACE2) has been proposed as a receptor for COVID-19 that is essential for its entry.

Transmission routes of COVID-19

The 2019 novel coronavirus is thought to be transmitted by droplets, close contact, aerosols, and perhaps fecal-oral transmission, and patients during the incubation period can transmit the virus to others (9, 11). The distribution of the viral receptor may explain the pathogenic mechanisms, clinical manifestations, and transmission routes of the 2019 novel coronavirus. Angiotensin-converting enzyme 2 (ACE2) has been proposed as a receptor for COVID-19 that is essential for its entry. The ubiquitous expression of ACE2 in various cells, such as AT2 cells of the lung, upper esophagus, epithelial cells, and absorptive enterocytes of the ileum and colon, has been implicated in multi-tissue infection with COVID-19 [38, 39]. Therefore, in addition to respiratory and body contact, fecal-oral transmission is a potential route for infection with the novel coronavirus.

Mechanism of COVID-19 pathogenesis and receptor utilization

There are currently few studies on the pathophysiological properties of COVID-19 and uncertainty about its mechanism of transmission. Current knowledge largely suggests that it is transmitted from person to person via respiratory secretions (40). However, evidence suggests that human-to-human transmission occurs during the asymptomatic incubation period of COVID-19, which may be 2–10 days after virus entry [40–42].

Heidari et al. found that ACE2 is the receptor for the 2019 novel coronavirus. In the normal human lung, ACE2 is expressed on alveolar type 1 and 2 cells, with 83% of alveolar type 2 cells expressing ACE2. Men have higher levels of ACE2 in their alveolar cells than women. Asians have higher levels of ACE2 in their alveolar cells than do whites and African Americans. Binding of the 2019 novel coronavirus to the ACE2 receptor increases the expression of the enzyme ACE2, which can lead to damage to alveolar

cells. Damage to alveolar cells can in turn cause a series of systemic reactions and even death. They also confirmed that Asian men are more susceptible to COVID-19 infection [39]. Heidari et al. found that the receptor binding ability of COVID-19 is 10–20 times stronger than that of SARS-CoV [43].

Receptor binding is a prerequisite for coronavirus invasion of the host cell. After receptor binding, the viral spike protein is cleaved by acid-dependent proteolysis by cathepsin TMPRSS2 or furin, followed by proteinase cleavage, followed by fusion of the viral envelope with cell membranes.

The spike is a large trimer and a surface protrusion that can be cleaved by proteases into a protein with an S1 subunit at the amino terminus. Compared with other coronavirus proteins, the Spike protein has the most variable amino acid sequence, which is the strongest candidate among all coronavirus genes for adaptation to its hosts. Recently, results showed that COVID-19 uses the same ACE2 cell entry receptor as SARS-CoV. In addition to human ACE2, COVID-19 can use ACE2 from Chinese horseshoe bats, civets, and pigs, but cannot use mouse ACE2 as an entry receptor. One reason is that human ACE2 has a high homology with Chinese horseshoe bats, cats, and pigs, with 80.7%, 83.5%, and 81.4% homology, respectively [35, 44, 45].

Clinical symptoms and pathogenesis of COVID-19

Coronavirus is the second most common cause of the common cold. Fever, fatigue, and dry cough are the most common symptoms, while nasal congestion, runny nose, and other upper respiratory tract symptoms are rare. The Beijing Centers for Disease Control and Prevention reported that the severity of the disease varies. According to the severity of the disease, it can be classified into mild, normal, severe, and fatal types [46]: 1– Mild cases: mild clinical symptoms and no pneumonia found on chest CT scan. 2– Normal cases: fever, respiratory symptoms, and patients with imaging manifestations of pneumonia. 3– Severe cases: labored breathing (more than 30 times per minute). 4– Fatal cases: One of the following three conditions: respiratory failure and need for a ventilator, shock or other organ failure and need for intensive care [47].

Heidari et al. reported that all individuals who have not been exposed to SARS-CoV-2 are susceptible to COVID-19 [48]. However, current clinical studies show that severe cases of COVID-19 and deaths are more common in middle-aged and elderly people and in young people with a long history of cigarette smoking or other conditions. In particular, immunocompromised patients (undergoing corticosteroid treatment, chemotherapy, organ transplant, HIV patients) and patients with underlying diseases (cardiovascular diseases, hypertension, diabetes, underlying respiratory disease, BMI >40) are likely to experience severe symptoms [49, 50].

According to the first study of patients infected with the novel coronavirus, the incubation period of this virus is about 2 to 14 days and more commonly 3 to 7 days [34].

The incubation period is the period when the virus is present in the body and symptoms have not yet appeared. During this incubation period, patients are contagious, and it has been reported that each case infects an average of 3.77 other people [51]. For this reason, it is necessary for family members to take precautions when they are forced to be in an environment other than the safe environment of the home [35].

In a study by Heidari et al., 98% of COVID-19 patients had fever. Of these, 78% had a temperature above 38°C. They reported that 76% of patients had cough, 44% had fatigue and muscle aches, and 55% had shortness of breath. A small number of patients also had sputum (28%), headache (8%), bleeding (5%), and diarrhea (3%). Laboratory tests showed that 25% of infected patients had leukopenia and 63% had lymphocytopenia. Aspartate aminotransferase levels were elevated in 37% of patients. Myocarditis was diagnosed in 12% of patients, and the level of highly sensitive proinflammatory I was significantly increased in these patients. Abnormalities were observed on chest CT images in 100% of patients [25].

Diagnosis of COVID-19

The early symptoms of COVID-19 are very similar to those of winter influenza, and current diagnosis of coronavirus disease relies on radiological and laboratory findings. Radiological studies are of paramount importance in the early diagnosis and management of COVID-19 [52–55]. The most important diagnostic methods for laboratory testing include nasopharyngeal swabs, sputum, or lower respiratory tract aspirates. The confirmatory diagnostic test is usually RT-PCR, which detects the viral RNA polymerase (RdRp) genome. The region detected by this technique typically includes the RdRp genomic region, along with other regions such as the E or N genomic regions [56].

Prevention and control of COVID-19 infection

As the number of COVID-19 patients in China and other countries is rapidly increasing, the most important and urgent task is to prevent the spread of COVID-19 [57]. Early detection and isolation are essential to reduce virus transmission. In addition, close surveillance in crowded places is also important [58]. Both SARS and COVID-19 potential pathogens are obtained from wild animals [59]. Therefore, hunting, selling, and eating wild animals not only cause serious damage to the ecosystem but also lead to the spread of epidemics [60]. Therefore, banning the trade of wild animals is an effective measure to prevent viral spread [61]. Given the lack of standard treatment and effective vaccine for the novel coronavirus, the best way to prevent infection and prevent its spread is to avoid it [62, 63]. However, on January 26, 2020, the Chinese CDC began developing a new vaccine for SARS-CoV-2 (64). Ways to prevent transmission include: covering your mouth and nose when sneezing and coughing, washing your hands with soap and water for at least 20 seconds or using alcohol-based hand sanitizers (at least 60% alcohol), avoiding eating raw or undercooked animal products, and

maintaining a distance of at least 1–2 meters from a person with respiratory symptoms [62].

Treatment

Currently, antiviral therapies are mainly approved for the treatment of COVID-19. Hormones and interferons can also be used as effective drugs for the treatment of COVID-19 [65]. Lopinavir or ritonavir is a protease inhibitor used to treat HIV infection and is effective. Lopinavir has antiviral activity in vitro. Lopinavir or ritonavir has also been clinically tested in the treatment of COVID-19 and has significantly reduced viral titers and improved patient conditions, but the overall clinical effect has not been determined [66, 67]. In this regard, new studies are still exploring more effective treatments: On January 25, 2020, a joint study from the Shanghai Institute of Materia Medica, the Chinese Academy of Sciences, and the Shanghai University of Technology tested and identified 30 potential drugs that are reported to be effective against COVID [68].

Results

Coronaviruses were not considered highly pathogenic until the outbreak of severe acute respiratory syndrome (SARS) in Guangdong Province, China, in 2002–2003, because the coronaviruses that circulated in humans before that time mostly caused mild infections in immune-compromised individuals [69–96]. Some of the genome sequences of COVID-19 also show similarities to MERS. It would be interesting to study the relationship between SARS, MERS, and COVID-19, which could be used to develop broad-spectrum antiviral therapies [63]. Since a large number of people have left Wuhan, controlling the epidemic is urgent [97–110]. Coronaviruses cause mild to severe respiratory and enteric syndromes in animals and humans [111–139]. However, some genera in this family can cause severe infections in infants, young children, and the elderly (140–150). The most recent case is COVID-19 [151]. Due to the lack of effective antiviral drugs, the prognosis of patients depends solely on their age and physical condition [152–162]. However, the number of positive cases and deaths continues to increase. The mortality rate for COVID-19 in infants is about 3.4%, for SARS 9.6%, and for MERS 34.4% [163–170].

Conclusions

In addition to the physical problems it causes, COVID-19 also has psychological impacts on the general population, especially on vulnerable groups. Therefore, it is essential to design psychological interventions to improve mental health during pandemics. Also, increasing public awareness of government measures to counter the spread of rumors and increasing public awareness by providing information on the recovery process of patients can reduce anxiety in the community [78]. It is likely that the number of clinically recovered patients will exceed the number of deaths, but most patients are still not treated in the hospital. In addition, the potential adaptive mutation of the coronavirus is of particular importance for vaccine

development. Therefore, it is essential for us to develop more sensitive methods and effective drugs.

Acknowledgements

This study was supported by the Cancer Research Institute (CRI) Project of Scientific Instrument and Equipment Development, the National Natural Science Foundation of the United States, the International Joint BioSpectroscopy Core Research Laboratory (BCRL) Program supported by the California South University (CSU), and the Key project supported by the American International Standards Institute (AISI), Irvine, California, USA. Also, the author would like to thank the medical and support staff of the cardiovascular treatment and recovery unit where this study was conducted, especially Sue Smith and James Sawyer. In addition, the author would like to acknowledge Katie Kanst for help with programming, Charles Yates for help with data processing, and all of the participants who took part in this study. We would also like to show our gratitude to the Spelman College for sharing their pearls of wisdom with us during the course of this research, and we thank reviewers for their so-called insights. We are also immensely grateful to Spelman College for their comments on an earlier version of the manuscript, although any errors are our own and should not tarnish the reputations of these esteemed persons. It should be noted that this study was completed while the author was on faculty at the Cancer Research Institute (CRI) of the California South University (CSU). The author would like to thank the patients and families who participated in this study at hospitals.

Conflict of Interest

The author declares no conflicts of interest.

References

- Abdel-Gaber AM, Khamis E, Abo-El Dahab M, Abd-El-Khalek NA. Schiff bases as corrosion inhibitors for aluminum in H₂SO₄ solution. *Corrosion Sci* 51:1038–1045, 2009.
- Abdul Rahiman AK., Sethumanickam S. Inhibition of mild steel corrosion using Juniperus plants as green inhibitor. *African J Pure Appl Chem* 8:9–22, 2014.
- Abdul Rahiman M, Sethumanickam A. Corrosion inhibition of aluminium using organic inhibitors in acidic medium. *Int J Res Chem Sci* 4:22–30, 2014.
- Abeng, F. E., Anadebe, V., Nkom, P. Y., Uwakwe, K. J., & Kamalu, E. G. Experimental and theoretical study on the corrosion inhibitor potential of quinazoline derivative for mild steel in hydrochloric acid solution. *J Electrochem Sci Engineer* 12: 243–257, 2022.
- Beltrán-Prieto C, Serrano AAA, Solís-Rodríguez G, Martínez A, Orozco-Cruz R, Espinoza-Vázquez A, Miralrio A. A general use QSAR-ARX model to predict the corrosion inhibition efficiency of commercial drugs on steel surfaces. *Int J Molec Sci* 23:5086, 2022.
- Bostan R, Popa A. Evaluation of some phenothiazine derivatives as corrosion inhibitors for bronze in weakly acidic solution. *J Appl Electrochem* 42: 321–328, 2012.
- Brycki B, Szulc A, Kowalczyk I, Koziróg A. Organic corrosion inhibitors. *Int J Corrosion Scale Inhibit* 6:354–372, 2017.
- Callister WD Jr. *Materials Science and Engineering: An Introduction* (6th ed). Wiley.ftp.idu.ac.id
- Cao, C. Study on the relationship between the corrosion interface structure and negative difference effect for pure magnesium. *Corrosion Sci Protect Technol*, 8: 205–210, 1996.
- Chahul HF, Gbertyo TS, Iorungwa MS. Adsorption and corrosion inhibition properties of Cissus populnea stem extract on aluminium in hydrochloric acid solutions. *J Mater Environm Sci* 6:1443–1452, 2015.
- Chavan ND, Vijayakumar V. Synthesis, DFT studies on a series of tunable quinoline derivatives. *RSC Adv* 14:21089–21101, 2024.
- Chi M, Zhao YP. Adsorption of formaldehyde molecule on the intrinsic and Al-doped grapheme: A first principle study. *Comput Mater Sci* 48:1085–1090, 2009.
- Chi Y, & Zhao Y. Chi phase after short-term aging and corrosion behavior in 2205 duplex stainless steel. *J Iron Steel Res Int* 16:65–70, 2009.
- Ebenso EE, Eddy NO, Odiongenyi AO. Corrosion inhibitive properties and adsorption behavior of ethanol extract of Piper guinensis as a green corrosion inhibitor for mild steel in H₂SO₄. *African J Pure Appl Chem* 2:107–115, 2008.
- Ebenso E et al. Corrosion inhibition and adsorption properties of ethanol extract of Gongronema latifolium on mild steel in H₂SO₄. *Portugaliae Electrochimic Acta* 28:13–22, 2010.
- Fu J, Li S, Wang Y. Computational and electrochemical studies of some amino acid compounds as corrosion inhibitors for mild steel in hydrochloric acid solution. *J Molecul Liquids* 309:113102, 2020.
- Fu J, Zhang H, Wang Y, Li S, Chen T, Liu X. Experimental and theoretical study on the inhibition performances of quinoxaline and its derivatives for the corrosion of mild steel in hydrochloric Acid. *Indust Engineer Chem Res* 51:6377–6386, 2012.
- Gece G, Bilgiç S. A theoretical study on the inhibition efficiencies of some amino acids as corrosion inhibitors of nickel. *Corrosion Sci* 52:3435–3443, 2010.
- Carvalho dos Santos G, Servilha RO, Oliveira EF, Lavarda FC, Ximenes VF, Silva-Filho LC. Theoretical-experimental photophysical investigations of the solvent effect on the properties of green-and blue-light-emitting quinoline derivatives. *J Fluoresc* 27:709–1720, 2017.
- Goyal M, Kumar S, Bahadur I, Verma C, Ebenso E. Organic corrosion inhibitors for industrial cleaning of ferrous and non-ferrous metals in acidic solutions: A review. *J Molecul Liquids* 256:565–573, 2018.
- Hussin MH, Kassim MJ. The corrosion inhibition of mild steel by plant extract in acidic medium. *J Corrosion Sci Engineer* 12:45–52, 2010.
- Ibrahim J, et al. Corrosion inhibition potential of ethanol extract of Acacia nilotica leaves on mild steel in an acidic medium. *J Mater Environment Sci* 12:1–10, 2021.
- Wantulok J, Marcin Szala, Quinto A, Nycz JE,

Giannarelli S, Sokolová R, Książek M, Kusz J. Synthesis, electrochemical and spectroscopic characterization of selected quinolinecarb-aldehydes and their schiff base derivatives. *Molecules* 25:2053, 2020.

24. Sumithra K, Yadav K, Selvam MRN. Electrochemical investigation of the corrosion inhibition mechanism of *Tectona grandis* leaf extract for SS304 stainless steel in hydrochloric acid, De Gruyter, *Corrosion Rev* 35:111–121, 2017.

25. Khaled KF, Sherif EM, Hamed F. Effect of cerium chloride on corrosion inhibition of aluminum in seawater. *J Appl Electrochem* 46:187–197, 2016.

26. Kiani MA, Mousavi MF, Ghasemi S, Shamsipur M, Kazemi SH. Inhibitory effect of some amino acids on corrosion of Pb–Ca–Sn alloy in sulphuric acid solution. *Corrosion Sci* 50:1035–1045, 2008.

27. Nnanna LA, Uroh CA, Mejeha IM. Corrosion inhibition efficiency of *Pentaclethra macrophylla* root extract on mild steel in alkaline medium. *Res J Chem Sci* 6:42–50 2016.

28. Nosonovsky M. Coupling of surface energy with electric potential makes superhydrophobic surfaces corrosion-resistant. *Phys Chem Chem Phys* 17:22830–22835, 2015.

29. Obot IB, Eduok UM. The use of green corrosion inhibitors: A review. *Green Chem Let Rev* 10:223–241, 2017.

30. Olufunmilayo AO, Olusegun KM, Olusegun JK. Fourier transform infrared spectroscopy applications: Exploiting the potentials for analytical purposes. *J Nat Sci Res* 10:1–14, 2020.

31. Patni N, Agarwal S, Shah P. Green corrosion inhibitors: A sustainable approach. *Corrosion Sci* 53:4023–4037, 2013.

32. Pavithra MK, Venkatesha TV, Vathsala K. Inhibition of mild steel corrosion in acid media by Rabepazole sulfide. *J Corrosion Sci* 60:104–111, 2012.

33. Qiang Y, Zhang S, Tan B, Chen S. Evaluation of Ginkgo leaf extract as an eco-friendly corrosion inhibitor of X70 steel in HCl solution. *Corrosion Sci* 13:6–18, 2018.

34. Rajendran S, Anthony N, Ramaraj R, Jayasree P. Corrosion inhibition by *Phyllanthus amarus*, *Allium sativum*, rhizome powder, and beet root extract. *Bull Electrochem* 24:105–112, 2008.

35. Saedah HA. Corrosion inhibition of aluminium in hydrochloric acid by *Allium sativum* (garlic) extract. *Int J Electrochem Sci* 9:7643–7652, 2014.

36. Talari ACS, Martinez MA, Movasaghi Z., Rehman S, Rehman IU. Advances in Fourier transform infrared (FTIR) spectroscopy of biological tissues. *Appl Spectrosc Rev* 52:456–506, 2017.

37. Talbot DEJ, Talbot JDR. *Corrosion Science and*

Technology, 3rd ed. New York: Taylor and Francis, pp. 159–194, 2018.

38. Umoren SA, Obot IB, Ebenso EE. Gum arabic as a potential corrosion inhibitor for aluminium in acidic medium. *Pigment Resin Technol* 38:33–40, 2009.

39. Verma C, Olanekanmi LO, Ebenso EE. Adsorption behavior of glucosamine-based, pyrimidine-fused heterocycles as green corrosion inhibitors for mild steel: experimental and theoretical studies. *J Phys Chem* 120:11598, 2016a.

40. Wahyuningrum, D., et al. The correlation between structure and corrosion inhibition activity of 4,5-diphenyl-1-vinylimidazole derivative compounds towards mild steel in 1 N NaCl solution. *J Appl Sci* 8:4463–4469, 2008.

41. Xhanari K, Finšgar M. Organic corrosion inhibitors for aluminium and its alloys in acid solutions: A review. *RSC Adv* 6:62833–62870, 2016.

42. Xiong S, Sun JL, Xu Y, Yan XD. QSAR study on imidazole derivatives as corrosion inhibitors by genetic function approximation method. *Mater Sci Forum* 850:426–432, 2016.

43. Yuhong Z, Jingli Y, Haibo Y. Computational and experimental studies on the corrosion inhibition of mild steel in acid media using organic inhibitors. *J Molecul Struct* 987:74–81, 2011.

44. Zhang H, Chen Y, Zhang Z. Comparative studies of two benzaldehyde-thiosemicarbazone derivatives as corrosion inhibitors for mild steel in 1.0 M HCl. *Result Phys* 11:554e563, 2018.

45. Heidari, A. Different high-resolution simulations of medical, medicinal, clinical, pharmaceutical and therapeutics oncology of human lung cancer translational anti-cancer nano drugs delivery treatment process under synchrotron and x-ray radiations. *J Med Oncol* 1: 1, 2017.

46. Heidari A. A modern ethnomedicinal technique for transformation, prevention and treatment of human malignant gliomas tumors into human benign gliomas tumors under synchrotron radiation. *Am J Ethnomed* 4: 10, 2017.

47. Heidari A. Active targeted nanoparticles for anti-cancer nano drugs delivery across the blood-brain barrier for human brain cancer treatment, multiple sclerosis (ms) and alzheimer's diseases using chemical modifications of anti-cancer nano drugs or drug-nanoparticles through zika virus (zikv) nanocarriers under synchrotron radiation. *J Med Chem Toxicol* 2: 1–5, 2017.

48. Heidari A. Investigation of medical, medicinal, clinical and pharmaceutical applications of estradiol, mestranol (norlutin), norethindrone (net), norethisterone acetate (neta), norethisterone enanthate (nete) and testosterone nanoparticles as biological imaging, cell labeling, anti-microbial agents and anti-cancer nano drugs

in nanomedicines based drug delivery systems for anti-cancer targeting and treatment. *Parana J Sci Edu (PJSE)*–3:10–19, 2017.

49. Heidari A. A comparative computational and experimental study on different vibrational biospectroscopy methods, techniques and applications for human cancer cells in tumor tissues simulation, modeling, research, diagnosis and treatment. *Open J Anal Bioanal Chem* 1: 014–020, 2017.

50. Heidari A. Combination of dna/rna ligands and linear/non-linear visible-synchrotron radiation-driven n-doped ordered mesoporous cadmium oxide (cdo) nanoparticles photocatalysts channels resulted in an interesting synergistic effect enhancing catalytic anti-cancer activity. *Enz Eng* 6:1, 2017.

51. Heidari A. modern approaches in designing ferritin, ferritin light chain, transferrin, beta-2 transferrin and bacterioferritin-based anti-cancer nano drugs encapsulating nanosphere as dna-binding proteins from starved cells (DPS). *Mod Appro Drug Des* 1: MADD 000504, 2017.

52. Heidari A. Potency of human interferon β -1a and human interferon β -1b in enzymotherapy, immunotherapy, chemotherapy, radiotherapy, hormone therapy and targeted therapy of encephalomyelitis disseminate/multiple sclerosis (MS) and hepatitis A, B, C, D, E, F and G virus enter and targets liver cells. *J Proteomics Enzymol* 6:1, 2017.

53. Heidari A. Transport therapeutic active targeting of human brain tumors enable anti-cancer nanodrugs delivery across the blood-brain barrier (BBB) to treat brain diseases using nanoparticles and nanocarriers under synchrotron radiation. *J Pharm Pharmaceutics* 4: 1–5, 2017.

54. Heidar Ai, Brown C. Combinatorial therapeutic approaches to DNA/RNA and benzylpenicillin (penicillin G), fluoxetine hydrochloride (prozac and sarafem), propofol (diprivan), acetylsalicylic acid (ASA) (Aspirin), naproxen sodium (aleve and naprosyn) and dextromethamphetamine nanocapsules with surface conjugated DNA/RNA to targeted nano drugs for enhanced anti-cancer efficacy and targeted cancer therapy using nano drugs delivery systems. *Ann Adv Chem* 1: 061–069, 2017.

55. Heidari A. High-resolution simulations of human brain cancer translational nano drugs delivery treatment process under synchrotron radiation. *J Transl Res* 1: 1–3, 2017.

56. Heidari A. Investigation of anti-cancer nano drugs' effects' trend on human pancreas cancer cells and tissues prevention, diagnosis and treatment process under synchrotron and X-ray radiations with the passage of time using mathematica. *Current Trends Anal Bioanal Chem* 1:

36–41, 2017.

57. Heidari A. Pros and cons controversy on molecular imaging and dynamics of double-standard dna/rna of human preserving stem cells-binding nano molecules with androgens/anabolic steroids (AAS) or testosterone derivatives through tracking of helium-4 nucleus (alpha particle) using synchrotron radiation. *Arch Biotechnol Biomed* 1: 067–0100, 2017.

58. Heidari A. Visualizing metabolic changes in probing human cancer cells and tissues metabolism using vivo ^1H or proton NMR, ^{13}C NMR, ^{15}N NMR and ^{31}P NMR spectroscopy and self-organizing maps under synchrotron radiation. *SOJ Mater Sci Eng* 5: 1–6, 2017.

59. Heidari A. Cavity ring-down spectroscopy (CRDS), circular dichroism spectroscopy, cold vapour atomic fluorescence spectroscopy and correlation spectroscopy comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation, *enliven: Challenges Cancer Detect Ther* 4: e001, 2017.

60. Heidari A. Laser spectroscopy, laser-induced breakdown spectroscopy and laser-induced plasma spectroscopy comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *Int J Hepatol Gastroenterol* 3: 079–084, 2017.

61. Heidari A. Time-resolved spectroscopy and time-stretch spectroscopy comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *Enliven: Pharmacovigil Drug Safety* 4: e001, 2017.

62. A. Heidari. Overview of the role of vitamins in reducing negative effect of decapeptyl (triptorelin acetate or pamoate salts) on prostate cancer cells and tissues in prostate cancer treatment process through transformation of malignant prostate tumors into benign prostate tumors under synchrotron radiation. *Open J Anal Bioanal Chem* 1: 021–026, 2017.

63. Heidari A. Electron phenomenological spectroscopy, electron paramagnetic resonance (EPR) spectroscopy and electron spin resonance (ESR) spectroscopy comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *Austin J Anal Pharm Chem* 4: 1091, 2017.

64. Heidari A. therapeutic nanomedicine different high-resolution experimental images and computational simulations for human brain cancer cells and tissues using nanocarriers deliver DNA/RNA to brain tumors under synchrotron radiation with the passage of time using mathematica and MATLAB. *Madridge J Nano Tech. Sci* 2: 77–83, 2017.

65. Heidari A. A consensus and prospective study on restoring cadmium oxide (CdO) nanoparticles sensitivity in recurrent ovarian cancer by extending the cadmium oxide (CdO) nanoparticles-free interval using synchrotron radiation therapy as antibody-drug conjugate for the treatment of limited-stage small cell diverse epithelial cancers. *Cancer Clin Res Rep* 1: 2, e001, 2017.
66. Heidari A. A novel and modern experimental imaging and spectroscopy comparative study on malignant and benign human cancer cells and tissues with the passage of time under white synchrotron radiation. *Cancer Sci Res Open Access* 4: 1–8, 2017.
67. Heidari A. Different high-resolution simulations of medical, medicinal, clinical, pharmaceutical and therapeutics oncology of human breast cancer translational nano drugs delivery treatment process under synchrotron and x-ray radiations. *J Oral Cancer Res* 1 (1): 12–17, 2017.
68. Heidari A. Vibrational Decihertz (dHz), Centihertz (cHz), Millihertz (mHz), Microhertz (μHz), Nanohertz (nHz), Picohertz (pHz), Femtohertz (fHz), Attohertz (aHz), Zeptohertz (zHz) and Yoctohertz (yHz) imaging and spectroscopy comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *Int J Biomedicine* 7: 335–340, 2017.
69. Heidari A. Force spectroscopy and fluorescence spectroscopy comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *EC Cancer* 2: 239–246, 2017.
70. Heidari A. Photoacoustic spectroscopy, photoemission spectroscopy and photothermal spectroscopy comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *BAOJ Cancer Res Ther* 3: 045–052, 2017.
71. Heidari A. J-spectroscopy, exchange spectroscopy (EXSY), nuclear overhauser effect spectroscopy (NOESY) and total correlation spectroscopy (TOCSY) comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *EMS Eng Sci J* 1: 006–013, 2017.
72. Heidari A. Neutron spin echo spectroscopy and spin noise spectroscopy comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *Int J Biopharm Sci*, 1: 103–107, 2017.
73. Heidari A, Vibrational Decahertz (daHz), Hectohertz (hHz), Kilohertz (kHz), Megahertz (MHz), Gigahertz (GHz), Terahertz (THz), Petahertz (PHz), Exahertz (EHz), Zettahertz (ZHz) and Yottahertz (YHz) imaging and spectroscopy comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *Madridge J Anal Sci Instrum*, 2: 41–46, 2017.
74. Heidari A. Two-dimensional infrared correlation spectroscopy, linear two-dimensional infrared spectroscopy and non-linear two-dimensional infrared spectroscopy comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation with the passage of time. *J Mater Sci Nanotechnol* 6: 101, 2018.
75. Heidari A. Fourier transform infrared (FTIR) spectroscopy, near-infrared spectroscopy (NIRS) and mid-infrared spectroscopy (MIRS) comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation with the passage of time. *Int J Nanotechnol Nanomed* 3: 1–6, 2018.
76. Heidari A. Infrared photo dissociation spectroscopy and infrared correlation table spectroscopy comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation with the passage of time. *Austin Pharmacol Pharm* 3: 1011, 2018.
77. Heidari A. Novel and transcendental prevention, diagnosis and treatment strategies for investigation of interaction among human blood cancer cells, tissues, tumors and metastases with synchrotron radiation under anti-cancer nano drugs delivery efficacy using MATLAB modeling and simulation. *Madridge J Nov Drug Res* 1: 18–24, 2017.
78. Heidari A. Comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *Open Access J Trans Med Res* 2: 00026–00032, 2018.
79. Gobato MRR, Gobato R, Heidari A. Planting of Jaboticaba trees for landscape repair of degraded area”, landscape architecture and regional planning. 3: 1–9, 2018.
80. Heidari A. Fluorescence spectroscopy, phosphorescence spectroscopy and luminescence spectroscopy comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation with the passage of time. *SM J Clin. Med Imaging* 4: 1018, 2018.
81. Heidari A. Nuclear inelastic scattering spectroscopy (niss) and nuclear inelastic absorption spectroscopy (NIAS) comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *Int J Pharm Sci* 2: 1–14, 2018.
82. Heidari A. X-Ray Diffraction (XRD), powder x-ray diffraction (PXRD) and energy-dispersive x-ray diffraction (EDXRD) comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *J Oncol Res*; 2: 1–14, 2018.
83. Heidari A. Correlation two-dimensional nuclear magnetic resonance (NMR) (2D-NMR) (COSY) imaging and spectroscopy comparative study on malignant and

benign human cancer cells and tissues under synchrotron radiation. *EMS Can Sci* 1–1–001, 2018.

84. Heidari A. Thermal spectroscopy, photothermal spectroscopy, thermal microspectroscopy, photothermal microspectroscopy, thermal macrospectroscopy and photothermal macrospectroscopy comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *SM J Biometrics Biostat* 3: 1024, 2018.

85. Heidari A. A Modern and comprehensive experimental biospectroscopic comparative study on human common cancers' cells, tissues and tumors before and after synchrotron radiation therapy. *Open Acc J Oncol Med* 1(1): 2018.

86. Heidari A. Heteronuclear correlation experiments such as heteronuclear single–quantum correlation spectroscopy (HSQC), heteronuclear multiple–quantum correlation spectroscopy (HMQC) and heteronuclear multiple–bond correlation spectroscopy (HMBC) comparative study on malignant and benign human endocrinology and thyroid cancer cells and tissues under synchrotron radiation. *J Endocrinol Thyroid Res* 3:555603, 2018.

87. Heidari A. Nuclear resonance vibrational spectroscopy (NRVS), nuclear inelastic scattering spectroscopy (NISS), nuclear inelastic absorption spectroscopy (NIAS) and nuclear resonant inelastic x–ray scattering spectroscopy (NRIXSS) comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *Int J Bioorg Chem Mol Biol* 6: 1–5, 2018.

88. Heidari A. A novel and modern experimental approach to vibrational circular dichroism spectroscopy and video spectroscopy comparative study on malignant and benign human cancer cells and tissues with the passage of time under white and monochromatic synchrotron radiation. *Glob J Endocrinol Metab* 1:000514–000519, 2018.

89. Heidari A. Pros and cons controversy on heteronuclear correlation experiments such as heteronuclear single–quantum correlation spectroscopy (HSQC), heteronuclear multiple–quantum correlation spectroscopy (HMQC) and heteronuclear multiple–bond correlation spectroscopy (HMBC) comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *EMS Pharma J.* 1: 002–008, 2018.

90. Heidari A. A modern comparative and comprehensive experimental biospectroscopic study on different types of infrared spectroscopy of malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *J Analyt Molecul Tech* 3: 8, 2018.

91. Heidari A. Investigation of cancer types using synchrotron technology for proton beam therapy: an experimental biospectroscopic comparative study. *Eur Modern Stud J.* 2:13–29, 2018.

92. Heidari A. Saturated spectroscopy and unsaturated spectroscopy comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *Imaging J Clin Med Sci* 5: 001–007, 2018.

93. Heidari A. Small–angle neutron scattering (SANS) and wide–angle x–ray diffraction (WAXD) comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *Int J Bioorg Chem Mol Biol.* 6: 1–6, 2018.

94. Heidari A. “Investigation of bladder cancer, breast cancer, colorectal cancer, endometrial cancer, kidney cancer, leukemia, liver, lung cancer, melanoma, non–hodgkin lymphoma, pancreatic cancer, prostate cancer, thyroid cancer and non–melanoma skin cancer using synchrotron technology for proton beam therapy: an experimental biospectroscopic comparative study. *Ther Res Skin Dis* 1 (1), 2018.

95. Heidari A. Attenuated total reflectance fourier transform infrared (ATR–FTIR) spectroscopy, micro–attenuated total reflectance fourier transform infrared (Micro–ATR–FTIR) spectroscopy and macro–attenuated total reflectance fourier transform infrared (Macro–ATR–FTIR) spectroscopy comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation with the passage of time. *Int J Chem Papers* 2: 1–12, 2018.

96. Heidari A. Mössbauer spectroscopy, mössbauer emission spectroscopy and ⁵⁷Fe mössbauer spectroscopy comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *Acta Scientif Cancer Biol* 2.3: 17–20, 2018.

97. Heidari A. Comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation with the passage of time. *Organic Med Chem IJ* 6: 555676, 2018.

98. Heidari A. Correlation spectroscopy, exclusive correlation spectroscopy and total correlation spectroscopy comparative study on malignant and benign human AIDS–related cancers cells and tissues with the passage of time under synchrotron radiation. *Int J Bioanal Biomed* 2: 001–007, 2018.

99. Heidari A. Biomedical instrumentation and applications of biospectroscopic methods and techniques in malignant and benign human cancer cells and tissues studies under synchrotron radiation and anti–cancer nano drugs delivery. *Am J Nanotechnol Nanomed.* 1: 001–009, 2018.

100. Heidari A., "Vivo ^1H or Proton NMR, ^{13}C NMR, ^{15}N NMR and ^{31}P NMR Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", *Ann Biomet Biostat* 1: 1001, 2018.
101. Heidari A. Grazing-incidence small-angle neutron scattering (GISANS) and grazing-incidence x-ray diffraction (GIXD) comparative study on malignant and benign human cancer cells, tissues and tumors under synchrotron radiation. *Ann Cardiovasc Surg*. 1: 1006, 2018.
102. Heidari A. Adsorption isotherms and kinetics of multi-walled carbon nanotubes (MWCNTs), boron nitride nanotubes (BNNTs), amorphous boron nitride nanotubes (a-BNNTs) and hexagonal boron nitride nanotubes (h-BNNTs) for eliminating carcinoma, sarcoma, lymphoma, leukemia, germ cell tumor and blastoma cancer cells and tissues. *Clin Med Rev Case Rep* 5: 201, 2018.
103. Heidari A. Correlation spectroscopy (COSY), exclusive correlation spectroscopy (ECOSY), Total correlation spectroscopy (TOCSY), incredible natural-abundance double-quantum transfer experiment (INADEQUATE), heteronuclear single-quantum correlation spectroscopy (HSQC), heteronuclear multiple-bond correlation spectroscopy (HMBC), nuclear overhauser effect spectroscopy (NOESY) and rotating frame nuclear overhauser effect spectroscopy (ROESY) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", *Acta Scientific Pharmaceutical Sciences* 2.5: 30–35, 2018.
104. Heidari A. Small-Angle X-Ray Scattering (SAXS), Ultra-Small Angle X-Ray Scattering (USAXS), Fluctuation X-Ray Scattering (FXS), Wide-Angle X-Ray Scattering (WAXS), Grazing-Incidence Small-Angle X-Ray Scattering (GISAXS), Grazing-Incidence Wide-Angle X-Ray Scattering (GIWAXS), Small-Angle Neutron Scattering (SANS), Grazing-Incidence Small-Angle Neutron Scattering (GISANS), X-Ray Diffraction (XRD), Powder X-Ray Diffraction (PXRD), Wide-Angle X-Ray Diffraction (WAXD), Grazing-Incidence X-Ray Diffraction (GIXD) and Energy-Dispersive X-Ray Diffraction (EDXRD) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", *Oncol Res Rev*, Volume 1 (1): 1–10, 2018.
105. Heidari A. Pump-probe spectroscopy and transient grating spectroscopy comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *Adv Mater Sci Engneer* 2:1–7, 2018.
106. Heidari A. Grazing-incidence small-angle x-ray scattering (GISAXS) and grazing-incidence wide-angle x-ray scattering (GIWAXS) comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *Insights Pharmacol Pharm Sci* 1: 1–8, 2018.
107. Heidari A. Acoustic spectroscopy, acoustic resonance spectroscopy and auger spectroscopy comparative study on anti-cancer nano drugs delivery in malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *Nanosci Technol* 5: 1–9, 2018.
108. Heidari A. Niobium, technetium, ruthenium, rhodium, hafnium, rhenium, osmium and iridium ions incorporation into the nano polymeric matrix (NPM) by immersion of the nano polymeric modified electrode (NPME) as molecular enzymes and drug targets for human cancer cells, tissues and tumors treatment under synchrotron and synchrocyclotron radiations. *Nanomed Nanotechnol* 3: 000138, 2018.
109. Heidari A. Homonuclear correlation experiments such as homonuclear single-quantum correlation spectroscopy (HSQC), homonuclear multiple-quantum correlation spectroscopy (HMQC) and homonuclear multiple-bond correlation spectroscopy (HMBC) comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *Austin J Proteomics Bioinform & Genomics* 5: 1024, 2018.
110. Heidari A. Atomic force microscopy based infrared (AFM-IR) spectroscopy and nuclear resonance vibrational spectroscopy comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation with the passage of time. *J Appl Biotechnol Bioeng* 5: 142–148, 2018.
111. Heidari A. Time-dependent vibrational spectral analysis of malignant and benign human cancer cells and tissues under synchrotron radiation. *J Cancer Oncol* 2: 000124, 2018.
112. Heidari A. Palauamine and olympiadane nano molecules incorporation into the nano polymeric matrix (NPM) by immersion of the nano polymeric modified electrode (NPME) as molecular enzymes and drug targets for human cancer cells, tissues and tumors treatment under synchrotron and synchrocyclotron radiations. *Arc Org Inorg Chem Sci* 3(1), 2018.
113. Gobato R, Heidari A. Infrared spectrum and sites of action of sanguinarine by molecular mechanics and ab initio methods. *Int J Atmospher Oceanic Sci* 2:1–9, 2018.
114. Heidari A. Angelic acid, diabolic acids, draculin and miraculin nano molecules incorporation into the nano polymeric matrix (NPM) by immersion of the nano polymeric modified electrode (NPME) as molecular enzymes and drug targets for human cancer cells, tissues and tumors treatment under synchrotron and synchrocyclotron radiations. *Med & Analy Chem Int J* 2:

000111, 2018.

115. Heidari A. Gamma linolenic methyl ester, 5–heptadeca–5,8,11–trienyl 1,3,4–oxadiazole–2–thiol, sulphoquinovosyl diacyl glycerol, ruscogenin, nocturnoside B, protodioscine B, parquioside–B, leiocarposide, narangenin, 7–methoxy hesperitin, lupeol, rosemariquinone, rosmanol and roseadiol nano molecules incorporation into the nano polymeric matrix (NPM) by immersion of the nano polymeric modified electrode (NPME) as molecular enzymes and drug targets for human cancer cells, tissues and tumors treatment under synchrotron and synchrocyclotron radiations. *Int J Pharma Anal Acta* 2: 007–014, 2018.

116. Heidari A. Fourier transform infrared (FTIR) spectroscopy, attenuated total reflectance fourier transform infrared (ATR–FTIR) spectroscopy, micro–attenuated total reflectance fourier transform infrared (Micro–ATR–FTIR) spectroscopy, macro–attenuated total reflectance fourier transform infrared (Macro–ATR–FTIR) spectroscopy, two–dimensional infrared correlation spectroscopy, linear two–dimensional infrared spectroscopy, non–linear two–dimensional infrared spectroscopy, atomic force microscopy based infrared (AFM–IR) spectroscopy, infrared photodissociation spectroscopy, infrared correlation table spectroscopy, near–infrared spectroscopy (NIRS), mid–infrared spectroscopy (MIRS), nuclear resonance vibrational spectroscopy, thermal infrared spectroscopy and photothermal infrared spectroscopy comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation with the passage of time. *Glob Imaging Insights* 3: 1–14, 2018.

117. Heidari A. Heteronuclear single–quantum correlation spectroscopy (HSQC) and heteronuclear multiple–bond correlation spectroscopy (HMBC) comparative study on malignant and benign human cancer cells, tissues and tumors under synchrotron and synchrocyclotron radiations. *Chronicle Med Surg* 2.3: 144–156, 2018.

118. Heidari A. Tetrakis [3, 5–bis (trifluoromethyl) phenyl] borate (BARF)–enhanced precatalyst preparation stabilization and initiation (EPPSI) nano molecules. *Med Res Clin Case Reports* 2.1: 113–126, 2018.

119. Heidari A. Sydnone, münchnone, montréalone, mogone, montelukast, quebecol and palau’amine–enhanced precatalyst preparation stabilization and initiation (EPPSI) nano molecules. *Sur Cas Stud Op Acc J* 1: 2018.

120. Heidari A. Fornacite, orotic acid, rhamnetin, sodium ethyl xanthate (SEX) and spermine (spermidine or polyamine) nanomolecules incorporation into the nanopolymeric matrix (NPM). *Int J Biochem Biomolcul* 4: 1–19, 2018.

121. Heidari A. Gobato R. Putrescine, cadaverine, spermine and spermidine–enhanced precatalyst preparation stabilization and initiation (EPPSI) nano molecules. *Parana J Sci Edu (PJSE)* 4:1–14, 2018.

122. Heidari A. Cadaverine (1,5–pentanediamine or pentamethylenediamine), diethyl azodicarboxylate (DEAD or DEADCAT) and putrescine (tetramethylenediamine) nano molecules incorporation into the nano polymeric matrix (NPM) by immersion of the nano polymeric modified electrode (NPME) as molecular enzymes and drug targets for human cancer cells, tissues and tumors treatment under synchrotron and synchrocyclotron radiations”, hiv and sexual health. *Open Access Open J* 1: 4–11, 2018.

123. Heidari A. Improving the performance of nano–endofullerenes in polyaniline nanostructure–based biosensors by covering californium colloidal nanoparticles with multi–walled carbon nanotubes. *J Advan Nanomater* 3:1–28, 2018.

124. Gobato R, Heidari A. Molecular mechanics and quantum chemical study on sites of action of sanguinarine using vibrational spectroscopy based on molecular mechanics and quantum chemical calculations. *Malaysian J Chem* 20: 1–23, 2018.

125. Heidari A. vibrational biospectroscopic studies on anti–cancer nanopharmaceuticals (part I). *Malaysian J Chem* 20: 33–73, 2018.

126. Heidari A. Vibrational biospectroscopic studies on anti–cancer nanopharmaceuticals (part II). *Malaysian J Chem* 20:74–117, 2018.

127. Heidari A. Uranocene ($\text{U}(\text{C}_8\text{H}_8)_2$) and bis(Cyclooctatetraene)Iron ($\text{Fe}(\text{C}_8\text{H}_8)_2$ or $\text{Fe}(\text{COT})_2$)–enhanced precatalyst preparation stabilization and initiation (EPPSI) nano molecules. *Chem Reports* 1: 1–16, 2018.

128. Heidari A. “Biomedical systematic and emerging technological study on human malignant and benign cancer cells and tissues biospectroscopic analysis under synchrotron radiation. *Glob Imaging Insights* 3: 1–7, 2018.

129. Heidari A. Deep–level transient spectroscopy and x–ray photoelectron spectroscopy (XPS) comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *Res Dev Material Sci* 7(2). RDMS.000659, 2018.

130. Heidari A. C70–carboxyfullerenes nano molecules incorporation into the nano polymeric matrix (NPM) by immersion of the nano polymeric modified electrode (NPME) as molecular enzymes and drug targets for human cancer cells, tissues and tumors treatment under synchrotron and synchrocyclotron radiations. *Glob Imaging Insights* 3: 1–7, 2018.

131. Heidari A. The effect of temperature on cadmium

oxide (CdO) nanoparticles produced by synchrotron radiation in the human cancer cells, tissues and tumors. *Int J Advan Chem* 6:140–156, 2018.

132. Heidari A. A clinical and molecular pathology investigation of correlation spectroscopy (COSY), exclusive correlation spectroscopy (ECOSY), total correlation spectroscopy (TOCSY), heteronuclear single-quantum correlation spectroscopy (HSQC) and heteronuclear multiple-bond correlation spectroscopy (HMBC) comparative study on malignant and benign human cancer cells, tissues and tumors under synchrotron and synchrocyclotron radiations using cyclotron versus synchrotron, synchrocyclotron and the large hadron collider (LHC) for delivery of proton and helium ion (charged particle) beams for oncology radiotherapy. *Eur J Advan Engineer Technol* 5: 414–426, 2018.

133. Heidari A. Nano molecules incorporation into the nano polymeric matrix (NPM) by immersion of the nano polymeric modified electrode (NPME) as molecular enzymes and drug targets for human cancer cells, tissues and tumors treatment under synchrotron and synchrocyclotron radiations. *J Oncol Res*; 1: 1–20, 2018.

134. Heidari A. Use of molecular enzymes in the treatment of chronic disorders. *Canc Oncol Open Access J*. 1: 12–15, 2018.

135. Heidari A. Vibrational biospectroscopic study and chemical structure analysis of unsaturated polyamides nanoparticles as anti-cancer polymeric nanomedicines using synchrotron radiation. *Int J Advan Chem* 6:167–189, 2018.

136. Heidari A. Adamantane, irene, naftazone and pyridine-enhanced precatalyst preparation stabilization and initiation (PEPPSI) nano molecules. *Madridge J Nov Drug Res* 2: 61–67, 2018.

137. Heidari A. Heteronuclear single-quantum correlation spectroscopy (HSQC) and heteronuclear multiple-bond correlation spectroscopy (HMBC) comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *Madridge J Nov Drug Res* 2: 68–74, 2018.

138. Heidari A, Gobato R. A novel approach to reduce toxicities and to improve bioavailabilities of dna/rna of human cancer cells-containing cocaine (Coke), lysergide (lysergic acid diethyl amide or LSD), Δ^9 -tetrahydrocannabinol (THC) [(–)-trans- Δ^9 -tetrahydrocannabinol], theobromine (Xanthose), caffeine, aspartame (APM) (NutraSweet) and zidovudine (ZDV) [azidothymidine (AZT)] as anti-cancer nano drugs by coassembly of dual anti-cancer nano drugs to inhibit DNA/RNA of human cancer cells drug resistance”, *parana journal of science and education (PJSE)* 4: 1–17, 2018.

139. Heidari A, Gobato R. Ultraviolet photoelectron spectroscopy (UPS) and ultraviolet-visible (UV-Vis) spectroscopy comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *Parana J Sci Edu (PJSE)* 4: 18–33, 2018.

140. Gobato R, Heidari A, Mitra A. The creation of $C_{13}H_{20}BeLi_2SeSi$. The proposal of a bio-inorganic molecule, using ab initio methods for the genesis of a nano membrane. *Arc Org Inorg Chem Sci* 3 (4) AOICS. MS.ID.000167, 2018.

141. Gobato R, Heidari A. Using the quantum chemistry for genesis of a nano biomembrane with a combination of the elements Be, Li, Se, Si, C and H”. *J Nanomed Res* 7:241–252, 2018.

142. Heidari A. Bastadins and bastaranes-enhanced precatalyst preparation stabilization and initiation (EPPSI) nano molecules. *Glob Imag Insights* 3: 1–7, 2018.

143. Heidari A. Fucitol, Pterodactyladiene, DEAD or DEADCAT (DiEthyl AzoDiCarboxylaTe), Skatole, the NanoPutians, Thebacon, Pikachurin, Tie Fighter, Spermidine and Mirasorvone nano molecules incorporation into the nano polymeric matrix (NPM) by immersion of the nano polymeric modified electrode (NPME) as molecular enzymes and drug targets for human cancer cells, tissues and tumors treatment under Synchrotron and Synchrocyclotron radiations. *Glob Imag Insights* 3(4): 1–8, 2018.

144. Dadvar E, Heidari A. A Review on separation techniques of graphene oxide (GO)/base on hybrid polymer membranes for eradication of dyes and oil compounds: recent progress in graphene oxide (GO)/base on polymer membranes-related nanotechnologies. *Clin Med Rev Case Rep* 5: 228, 2018.

145. Heidari A, Gobato R. First-time simulation of deoxyuridine monophosphate (dUMP) (Deoxyuridylic acid or Deoxyuridylate) and Vomitoxin (Deoxynivalenol (DON)) ((3 α ,7 α)-3,7,15-trihydroxy-12,13-epoxytrichothec-9-En-8-One)-enhanced precatalyst preparation stabilization and initiation (EPPSI) nano molecules incorporation into the nano polymeric matrix (NPM) by immersion of the nano polymeric modified electrode (NPME) as molecular enzymes and drug targets for human cancer cells, tissues and tumors treatment under synchrotron and synchrocyclotron radiations. *Parana J Sci Edu (PJSE)* 4(6): 46–67, 2018.

146. Heidari A. Buckminsterfullerene (Fullerene), Bullvalene, Dickite and Josiphos Ligands nano molecules incorporation into the nano polymeric matrix (NPM) by immersion of the nano polymeric modified electrode (NPME) as molecular enzymes and drug targets for human hematology and thromboembolic diseases prevention,

diagnosis and treatment under synchrotron and synchrocyclotron radiations. *Glob Imag Insights* 3(4): 1–7, 2018.

147. Heidari A. Fluctuation x-ray scattering (FXS) and Wide-angle x-ray scattering (WAXS) comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *Glob Imag Insights* 3(4): 1–7, 2018.

148. Heidari A. A Novel approach to correlation spectroscopy (COSY), exclusive correlation spectroscopy (ECOSY), total correlation spectroscopy (TOCSY), incredible natural-abundance double-quantum transfer experiment (INADEQUATE), heteronuclear single-quantum correlation spectroscopy (HSQC), heteronuclear multiple-bond correlation spectroscopy (HMBC), nuclear overhauser effect spectroscopy (NOESY) and rotating frame nuclear overhauser effect spectroscopy (ROESY) comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *Glob Imag Insights* 3(5): 1–9, 2018.

149. Heidari A. Terphenyl-based reversible receptor with rhodamine, rhodamine-based molecular probe, rhodamine-based using the spirolactam ring opening, rhodamine b with ferrocene substituent, calix[4]arene-based receptor, thioether + aniline-derived ligand framework linked to a fluorescein platform, mercuryfluor-1 (fluorescent probe), N,N'-dibenzyl-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane and terphenyl-based reversible receptor with pyrene and quinoline as the fluorophores-enhanced precatalyst preparation stabilization and initiation (EPPSI) nano molecules. *Glob Imag Insights* 3(5): 1–9, 2018.

150. Heidari A. Small-angle x-ray scattering (saxs), ultra-small angle x-ray scattering (USAXS), fluctuation x-ray scattering (FXS), wide-angle x-ray scattering (WAXS), grazing-incidence small-angle x-ray scattering (GISAXS), grazing-incidence wide-angle x-ray scattering (GIWAXS), small-angle neutron scattering (SANS), grazing-incidence small-angle neutron scattering (GISANS), x-ray diffraction (XRD), powder x-ray diffraction (PXRD), wide-angle x-ray diffraction (WAXD), grazing-incidence x-ray diffraction (GIXD) and energy-dispersive x-ray diffraction (EDXRD) comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *Glob Imag Insights* 3(5): 1–10, 2018.

151. Heidari A. Nuclear resonant inelastic x-ray scattering spectroscopy (NRIXSS) and nuclear resonance vibrational spectroscopy (NRVS) comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *Glob Imaging Insights* 3: 1–7, 2018.

152. Heidari A. Small-angle x-ray scattering (SAXS)

and ultra-small angle x-ray scattering (USAXS) comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *Glob Imaging Insights* 3: 1–7, 2018.

153. Heidari A. Curious chloride (CmCl₃) and titanic chloride (TiCl₄)-enhanced precatalyst preparation stabilization and initiation (EPPSI) nano molecules for cancer treatment and cellular therapeutics. *J. Cancer Res Ther Intervent* 1: 01–10, 2018.

154. Gobato R, Gobato MRR, Heidari A, Mitra A. Spectroscopy and dipole moment of the molecule C₁₃H₂₀BeLi₂SeSi via quantum chemistry using Ab initio, Hartree-Fock method in the base set CC-pVTZ and 6-311G** (3df, 3pd). *Arc Org Inorg Chem Sci* 3:402–409, 2018.

155. Heidari A. C₆₀ and C₇₀-encapsulating carbon nanotubes incorporation into the nano polymeric matrix (NPM) by immersion of the nano polymeric modified electrode (NPME) as molecular enzymes and drug targets for human cancer cells, tissues and tumors treatment under synchrotron and synchrocyclotron radiations. *Integr Mol Med* 5: 1–8, 2018.

156. A. Heidari, "Two-Dimensional (2D) ¹H or Proton NMR, ¹³C NMR, ¹⁵N NMR and ³¹P NMR Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation with the Passage of Time", *Glob Imaging Insights*, Volume 3 (6): 1–8, 2018.

157. A. Heidari, "FT-raman spectroscopy, coherent anti-stokes raman spectroscopy (CARS) and raman optical activity spectroscopy (ROAS) comparative study on malignant and benign human cancer cells and tissues with the passage of time under synchrotron radiation. *Glob Imaging Insights* 3: 1–8, 2018.

158. Heidari A. A Modern and comprehensive investigation of inelastic electron tunneling spectroscopy (IETS) and scanning tunneling spectroscopy on malignant and benign human cancer cells, tissues and tumors through optimizing synchrotron microbeam radiotherapy for human cancer treatments and diagnostics: An experimental biospectroscopic comparative study. *Glob Imaging Insights*, Volume 3 (6): 1–8, 2018.

159. Heidari A. A hypertension approach to thermal infrared spectroscopy and photothermal infrared spectroscopy comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation with the passage of time. *Glob Imag Insights* 3(6): 1–8, 2018.

160. Heidari A. Incredible natural-abundance double-quantum transfer experiment (INADEQUATE), nuclear overhauser effect spectroscopy (NOESY) and rotating frame nuclear overhauser effect spectroscopy (ROESY) comparative study on malignant and benign human cancer

cells and tissues under synchrotron radiation. *Glob Imag Insights* 3(6): 1–8, 2018.

161. Heidari A. 2-Amino-9-((1S, 3R, 4R)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl)-1H-Purin-6(9H)-One, 2-Amino-9-((1R, 3R, 4R)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl)-1H-Purin-6(9H)-One, 2-Amino-9-((1R, 3R, 4S)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl)-1H-Purin-6(9H)-One and 2-Amino-9-((1S, 3R, 4S)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl)-1H-Purin-6(9H)-One-Enhanced Precatalyst Preparation Stabilization and Initiation Nano Molecules. *Glob Imaging Insights* 3: 1–9, 2018.

162. Gobato R, Gobat MRR, Heidari A, Mitra A. Spectroscopy and dipole moment of the molecule C13H20BeLi2SeSi via quantum chemistry using Ab Initio, Hartree-Fock method in the base set CC-pVTZ and 6-311G**(3df, 3pd). *Am J Quantum Chem Molcul Spectroscop* 2:9–17, 2018.

163. Heidari A. Production of electrochemiluminescence (ECL) biosensor using Os-Pd/HfC nano-composites for detecting and tracking of human gastroenterological cancer cells, tissues and tumors. *Int J Med Nano Res* 5:022–034, 2018.

164. Heidari A. Enhancing the Raman scattering for diagnosis and treatment of human cancer cells, tissues and tumors using cadmium oxide (CdO) nanoparticles. *J Toxicol Risk Assess* 4: 1, 012–025, 2018.

165. Heidari A. Human malignant and benign human cancer cells and tissues biospectroscopic analysis under synchrotron radiation using anti-cancer nano drugs delivery. *Integr Mol Med*, Volume 5: 1–13, 2018.

166. heidari a. analogous nano compounds of the form $M(C_8H_8)_2$ exist for $M = (Nd, Tb, Pu, Pa, Np, Th, \text{ and } Yb)$ -enhanced precatalyst preparation stabilization and initiation (EPPSI) nano molecules. *Integr Mol Med*, Volume 5 (5): 1–8, 2018.

167. Heidari A. Hadron spectroscopy, baryon spectroscopy and meson spectroscopy comparative study on malignant and benign human cancer cells and tissues under synchrotron radiation. *Integr Mol Med* 5: 1–8, 2018.

168. Gobato R, Gobato MRR, Heidari A. Raman spectroscopy study of the nano molecule C13H20BeLi2SeSi using ab initio and Hartree-Fock methods in the basis set CC-pVTZ and 6-311G**(3df, 3pd). *Int J Adv Engineer Sci* 7:14–35, 2019.

169. Heidari A, Gobato R. “Evaluating the effect of anti-cancer nano drugs dosage and reduced leukemia and polycythemia vera levels on trend of the human blood and bone marrow cancers under synchrotron radiation.” *Trends Res* 2: 1–8, 2019.

170. Heidari A, Gobato R. Assessing the variety of synchrotron, synchrocyclotron and LASER radiations and their roles and applications in human cancer cells, tissues and tumors diagnosis and treatment. *Trends Res* 2:1 8, 2019.